ArticleFrontiers in oncology2025
Individualization of clinical target volume delineation in eccentric nasopharyngeal carcinoma: a prospective comparative study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06167109 (Endoscopic NBI Combined With MRI to Guide the Optimization of Clinical Target Volume Delineation in Eccentric Nasopharyngeal Carcinoma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Endoscopic NBI Combined With MRI to Guide the Optimization of Clinical Target Volume Delineation in Eccentric Nasopharyngeal Carcinoma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clinical target volume (CTV) delineation is a major focus in radiotherapy for nasopharyngeal carcinoma (NPC) and currently lacks a universally accepted standard across treatment centers. We proposed an individualized CTV delineation method for eccentric NPC and evaluated its feasibility based on the eccentric distance of the primary lesion. Materials and methods: Ninety patients with eccentric NPC were included. Each treatment plan was replanned using the individualized CTV method for dosimetric comparison with the conventional CTV, to evaluate coverage, homogeneity, and conformity of CTV and PTV, sparing of organs at risk (OARs) and radiotherapy technique. Paired sample t-tests and nonparametric rank-sum tests were used to compare target coverage, homogeneity, conformity, and OAR dose parameters between the two approaches. Correlation analysis is used to evaluate the correlation between eccentric distance of primary lesion and OARs dose changes. Subgroup analysis is used to compare the PTV and OARs dose parameters of individualized CTV at different T stages or radiotherapy techniques. Results: Our results showed that compared with conventional CTV, the volume of CTV decreased significantly (P< 0.05) through individualizing delineation for eccentric NPC, especially CTV1 volume (95.81 cm³ vs. 57.57 cm³, P < 0.001). Individualized CTV reduced the doses delivered to OARs, including the brainstem, spinal cord, optic chiasm, optic nerves, and contralateral temporal lobe, inner ear and so on (all P< 0.05). When the eccentric distance of the primary lesion was between 1.4 and 2.1 cm, the individualized CTV approach provided significant advantages in organ protection, such as contralateral optic nerve, temporal lobe and parotid gland. Additionally, Subgroup analysis showed that the dose-sparing benefit of individualized CTV was more pronounced in patients treated with VMAT (volumetric modulated arc therapy). Conclusion: This study demonstrates the dosimetric advantages of individualized CTV delineation based on eccentric distance. Our prospective trial is currently ongoing for further research (NCT06167109).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.